NR NR NR 2,871 per QALY gained o Patients with CHF and LVSD aged 75 years 1. n/a 1. n/a - - 2. NR 2. NR Baseline Probability cost- 3. NR 3. NR NR NR 5,392 per QALY gained Monitoring Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Study Applicability Limitations Other comments Costs Effects Inc. cost Inc. effects Cost- effectiveness Uncertainty o Patients with CHF of any cause QALY gained Probability cost- QALY gained Probability cost- o Patients with CHF of any cause aged 1. NR 1. NR Baseline - 2. NR 2. NR NR NR Extendedly dominated - 3. NR 3. NR NR NR 2,517 per QALY gained Probability cost-effective o Patients with CHF of any cause aged 1. NR 1. NR Baseline Probability cost- 2. NR 2. NR NR NR 11,508 per QALY gained 3. NR 3. NR NR NR Dominated. - Moertl [Austria] Partially applicable(c) Potentially Serious Limitations (d) Cost-utility analysis, Markov model Comparators: 1. Usual care in community 2. Nurse-led MDT 3. NT-proBNP guided intensive management 20 year time horizon effective) - effective) - threshold): NR Monitoring Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: Study Applicability Limitations Other comments Costs Effects Inc. cost Inc. effects Cost- effectiveness Uncertainty modelled Pufulete (Mohiud ) [UK] Directly applicable(e) Minor Limitations (f) Cost-utility analysis, Markov model Comparators: clinically-guided therapy 2. 